Pharmaceutical Technology
NOVEMBER 4, 2023
QL-325 is under clinical development by QLSF Biotherapeutics and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia).
Drug Patent Watch
NOVEMBER 4, 2023
This chart shows the drugs with the most patents in Morocco. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.… The post Which pharmaceutical drugs have the most drug patents in Morocco? appeared first on DrugPatentWatch - Make Better Decisions.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
NOVEMBER 4, 2023
MBX-1416 is under clinical development by MBX Biosciences Inc and currently in Phase II for Hypoglycemia.
Pharmaceutical Technology
NOVEMBER 4, 2023
D3L-001 is under clinical development by D3 Bio and currently in Phase I for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer).
Pharmaceutical Technology
NOVEMBER 4, 2023
D3L-001 is under clinical development by D3 Bio and currently in Phase I for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer).
Pharmaceutical Technology
NOVEMBER 4, 2023
Debio-4127 is under clinical development by Debiopharm International and currently in Phase II for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET).
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharmaceutical Technology
NOVEMBER 4, 2023
QL-325 is under clinical development by QLSF Biotherapeutics and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia).
Pharmaceutical Technology
NOVEMBER 4, 2023
D3L-001 is under clinical development by D3 Bio and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas.
Pharmaceutical Technology
NOVEMBER 4, 2023
D3L-001 is under clinical development by D3 Bio and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas.
Pharmaceutical Technology
NOVEMBER 4, 2023
HUC-3443 is under clinical development by Huons and currently in Phase II for Idiopathic (Essential) Hypertension.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharmaceutical Technology
NOVEMBER 4, 2023
HUC-3443 is under clinical development by Huons and currently in Phase II for Idiopathic (Essential) Hypertension.
Pharmaceutical Technology
NOVEMBER 4, 2023
RPA-601 is under clinical development by Rocket Pharmaceuticals and currently in Phase I for Cardiomyopathy.
Pharmaceutical Technology
NOVEMBER 4, 2023
RPA-601 is under clinical development by Rocket Pharmaceuticals and currently in Phase I for Cardiomyopathy.
Pharmaceutical Technology
NOVEMBER 4, 2023
MBX-1416 is under clinical development by MBX Biosciences Inc and currently in Phase II for Hypoglycemia.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Pharmaceutical Technology
NOVEMBER 4, 2023
Melpida is under clinical development by Elpida Therapeutics and currently in Phase II for Paraplegia.
Pharmaceutical Technology
NOVEMBER 4, 2023
PHIN-214 is under clinical development by PharmaIN and currently in Phase I for Portal Hypertension.
Pharmaceutical Technology
NOVEMBER 4, 2023
PHIN-214 is under clinical development by PharmaIN and currently in Phase I for Portal Hypertension.
Pharmaceutical Technology
NOVEMBER 4, 2023
HUC-3443 is under clinical development by Huons and currently in Phase II for Hypercholesterolemia.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Pharmaceutical Technology
NOVEMBER 4, 2023
HUC-3443 is under clinical development by Huons and currently in Phase II for Hypercholesterolemia.
Expert insights. Personalized for you.
130 
Let's personalize your content